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Periodontal diseases are chronic, multifactorial inflammatory diseases that affect 
more than 10% of the world population. There are two general forms of periodontal 
diseases including gingivitis (reversible inflammation and confined with gingiva 
form) and periodontitis (irreversible, destruction form). Several studies have reported 
that periodontal disease was associated with a decreased antioxidant capacity and 
elevated oxidative damage within the oral cavity. Glutathione peroxidase (GSH-Px) is 
an important enzymatic antioxidant that protects periodontal tissues against oxidative 
stress. Hitherto, there is contradictory evidence concerning the relationship between 
the levels of GSH-Px and the periodontal status. Various studies have demonstrated 
that GSH-Px levels in different biological fluids increased, decreased, or are unaltered 
in individuals with periodontal disease. This discrepancy might be explained either 
by different determination protocols/assays applied among the studies or various 
dynamic processes of the periodontal disease progression. In this section, GSH-Px 
levels are summarized in the periodontal health and disease including the presence 
and absence of systemic disease, medication, wound healing, and smoking.
Keywords: glutathione peroxidase, periodontitis, gingivitis, gingival crevicular fluid, 
salivary
1. Introduction
The periodontium is a private connective tissue consisting of a gingiva, 
cementum, periodontal ligament, and alveolar bone supporting the tooth in the 
socket [1]. Periodontal disease is a widespread, chronic multimicrobial immuno-
inflammatory illness which began with the complex coaction between the host’s 
immunoinflammatory responses and pathogenic bacteria in the dental tissue [2]. 
There are two general forms of periodontal diseases including gingivitis (confined 
with gingiva form) and periodontitis. Gingivitis is a localized inflammation of the 
gingiva, which is began by pathogens in the microbial dental plaque on the tooth 
and gingiva [3]. Gingivitis causes reversible inflammation in the periodontal tissues 
[3]. Periodontitis, the destructive form of periodontal disease, leads to the destruc-
tion of the gingiva, alveolar bone, and periodontal ligament and is responsible for 
causing tooth mobility and early tooth loss [3, 4]. Periodontitis leads to irreversible 
local periodontal tissue destruction [5]. Periodontal diseases are the most common 
chronic diseases impacting 10–15% of population worldwide [6, 7].
Microbial dental plaque, mostly gram-negative anaerobic or facultative patho-
gens inside the subgingival biofilm, is the principal etiological factor in periodontal 
diseases [8]. Robust evidence in the etiology of periodontal diseases has been shown 
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responsible for periodontopathogens including Aggregatibacter actinomycetemcomitans 
(Aa), Porphyromonas gingivalis (PG), Tannerella forsythia (TF), and Treponema dentic-
ola (TD) [9]. It is stated that “red complex” pathogens (PG, TD, and TF) are frequent 
in individuals with periodontitis [10]. The plurality of periodontal tissue devasta-
tion is brought about by an unsuitable host response to those pathogens and their 
products (lipopolysaccharides and proteases) [11]. The coaction between pathogenic 
bacteria and the host’s immune response is participated by chemokines, the produce 
of pro-inflammatory cytokines, and an exaggerated immune response, entailing an 
increase in the number and activity of polymorphonuclear leukocytes (PMNs) [12]. 
PMNs are the main mediators of host response averse to the bacteria [13].
PMNs create the first advocacy of cellular host defenses averse to pathogenic 
microorganisms in the gingival sulcus [14]. PMNs defend the host against bacteria 
in two pathways, including oxygen-dependent and non-oxygen-dependent mecha-
nisms [15]. The oxygen-dependent pathway contains the production of reactive 
oxygen species (ROS), which causes the destruction of periodontal tissues [16]. 
Although the main reason for the production of ROS by PMNs is the killing of bac-
teria, excessive production of ROS in the extracellular space causes the destruction 
of tissues [8, 14, 16]. The overproduction of ROS leads to tissue damage through 
different mechanisms including lipid peroxidation, DNA and protein damage, and 
the stimulation of pro-inflammatory cytokine [1, 16]. Several studies have shown 
the relationship between ROS and periodontal disease [5, 16–18]. Oxidative stress 
(OS), an imbalance between the pro-oxidant and antioxidant system, is involved 
in the bone resorptive process during periodontal disease [19]. Various studies have 
shown that OS is involved in the pathophysiological mechanisms of periodontitis 
[1, 17, 18, 20, 21]. Recently Sreeram et al. have described it as follows: “Periodontitis 
is an inflammatory condition leading to increased OS” [22].
Antioxidant defense mechanisms (nonenzymatic and enzymatic antioxidants) 
eliminate ROS and inhibit their detrimental consequences on the host [23]. 
Antioxidant enzymes protect tissues against the destructive effects of ROS cre-
ated by different metabolic processes, modulating the dimension of inflammatory 
response [18, 24]. The defense mechanism averse to ROS involves three antioxidant 
pathways including intracellular, extracellular, and membrane antioxidants [25]. 
The main system is intracellular ROS cleaning enzymes: superoxide dismutase 
(SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) [25]. GSH-Px, as a 
selenium-containing peroxidase, is a major group of enzymes that eliminate hydro-
gen peroxide created by SOD in the cytosol and mitochondria by oxidizing reduced 
glutathione to its oxidized form [22, 26]. GSH-Px is one of the enzymes that has a 
significant role in host defense averse to oxidative stress in cytosol [1, 18]. GSH-Px1 
inhibits cytotoxic peroxide-induced oxidative damage, protein degeneration, and 
lipid peroxidation [27].
Traditional diagnosis of periodontal disease is based on clinical (gingival index 
(GI), bleeding on probing (BOP), clinical attachment level (CAL), probing pocket 
depth (PPD)) and radiographic parameters [22]. Traditional clinical measurements 
that are used for periodontal diagnosis are frequently of only restricted usefulness 
inasmuch as they are indicators of previous periodontal disease rather than present 
disease activity [28, 29]. Knowing the disease activity will enable early detection 
of the disease [21]. Moreover, the levels of oxidative stress parameters in saliva and 
gingival crevicular fluid (GCF) may show the activity and severity of periodontal 
disease [29].
Saliva is used as an easily collected diagnostic fluid that makes it possible to deter-
mine the levels of biomarkers in the evaluation of the disease condition [30]. By the 
way, GCF is a biological fluid in the gingival sulcus that derives from blood plasma 
and consists of metabolic elements of pathogens and host cells, which are explained 
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as transudates or exudates [31]. Thereby, disease diagnosis via analysis of saliva and 
GCF is suitable for individuals [21]. Since the half-life of ROS is very short, they 
cannot be determined easily. Thus, ROS-induced demolition products and the activ-
ity of enzymatic and nonenzymatic antioxidants are optimal candidates to assess 
the consequences of OS-connected events in the pathological process of chronic 
periodontitis [21]. On the other hand, antioxidants (enzymatic and nonenzymatic 
antioxidants) in the saliva preserve the unity of oral tissues by neutralizing ROS [14].
In this section, GSH-Px levels are summarized in the periodontal health and 
disease including the presence and absence of systemic disease, medication, wound 
healing, smoking.
2. Glutathione peroxidase and periodontal disease
Wei et al. [32] examined the role of glutathione peroxidase in the pathogenesis 
of periodontal diseases. They reported higher total amount of GSH-Px in GCF 
samples from patients with gingivitis and periodontitis compared to healthy 
subjects [32]. Moreover, they determined that the total amount of GSH-Px was sig-
nificantly higher in periodontitis patients than in gingivitis patients [32]. Also, there 
is a positive and significant correlation between the total amount of glutathione 
peroxidase and interleukin (IL)-1β and plaque index (PI) in GCF of the individuals 
with periodontal disease [32]. Besides, Panjamurthy et al. [33] assessed the levels of 
GSH-Px in patients with chronic periodontitis (CP) and determined that GSH-Px 
activities in the plasma, erythrocyte lysate, and gingival tissues were significantly 
increased in patients with periodontitis compared to healthy subjects. In addition, 
Borges et al. [34] analyzed the GSH-Px activities in the gingival tissue of individu-
als with CP. They determined a significant increase in GSH-Px activities in the 
individuals with CP when compared to the control group [34]. They noticed that an 
increase in GSH-Px may indicate possible antioxidant suppression in the destroyed 
ROS products in the gingival tissue [34]. Moreover, Arunachalam et al. [35] stated 
that the GSH-Px levels in the plasma of patients with aggressive periodontitis 
increased compared with the healthy individuals. Conversely, Sreeram et al. [22] 
and Aziz et al. [36] reported that serum GSH-Px activity in individuals with CP 
decreased when compared with the control groups.
Tsai et al. [37] aimed to determine the GSH-Px levels in saliva before and after 
periodontal treatment in patients with CP. They did not find a significant difference 
in the activities of GSH-Px in saliva between periodontally diseased and healthy 
subjects and even between prior to and after treatment in periodontitis patients 
[37]. On the contrary, Çanakçı et al. [20] and Miricescu et al. [38] found that the 
GSH-Px activities in saliva of patients with periodontitis were significantly lower 
than the controls. In accordance with Tsai et al. [37], Çanakcı et al. [20] suggested 
that there were no significant correlations between salivary GSH-Px capacities 
and periodontal status. Contrary to Tsai et al. [37], Novaković et al. [14, 39] evalu-
ated the GSH-Px activity in saliva of the CP patients before and after nonsurgical 
treatment and concluded that there was a significant increase in these levels after 
therapy. Novaković et al. [14] argued that the increase in GSH-Px activity in saliva 
can be explained by the reduction in periodontal tissue inflammation after nonsur-
gical therapy. Novaković et al. [39] indicated that salivary GSH-Px could be used 
as a reliable biomarker in evaluating periodontal status and therapy outcome. A 
recent meta-analysis declared that there are no significant differences in the salivary 
GSH-Px levels between the patients with CP and periodontally healthy individuals 
[21]. These meta-analysis results coincide with other studies that have determined 
an increase or decrease in salivary GSH-Px levels [21]. The authors claimed that this 
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disagreement might be connected to the various dynamic processes of the peri-
odontitis progression [21].
Almerich-Silla et al. [17] showed the association between GSH-Px levels and the 
presence of different periodontal pathogens (PG, Aa, TD, and TF). They reported 
that GSH-Px levels were elevated in the existence of all bacteria types, except PG 
genotypes III and IV, and also the presence of different types of bacteria has a 
positive relationship with GSH-Px [17]. The authors advised that determination 
of GSH-Px levels and periodontal bacteria can be an important tool to control the 
progression of periodontal disease [17].
Until today, there is contradictory evidence concerning the relationship between 
the levels of GSH-Px and the periodontal status. Various studies have demonstrated 
that GSH-Px levels in different biological fluids increased, decreased, or are unal-
tered in individuals with periodontal disease. This discrepancy might be explained 
by different determination protocols/assays applied among the studies. On the 
other hand, a more persuasive change in GSH-Px activity in GCF than in saliva is 
observed [40]. GCF is more specific for periodontal inflammation than saliva, and 
also, saliva and serum GSH-Px levels may be affected by systemic conditions.
Replace the entirety of this text with the main body of your chapter. The body 
is where the author explains experiments, presents and interprets data of one’s 
research. Authors are free to decide how the main body will be structured. However, 
you are required to have at least one heading. Please ensure that either British or 
American English is used consistently in your chapter.
2.1 Plasma glutathione peroxidase and periodontal disease
Patel et al. [8] examined the levels of plasma glutathione peroxidase (eGPx) in 
GCF before and 6–8 weeks after periodontal therapy in patients with periodontal 
disease. They ascertained that eGPx levels in GCF were significantly elevated 
progressively from health to gingivitis and periodontitis [8]. The study suggested 
that increased eGPx level in GCF from inflamed gingiva may indicate the increased 
ROS generation at the diseased site [8]. Also, the authors determined that the mean 
concentration of eGPx in GCF in CP group showed a significant reduction after the 
treatment and thus stated that increased eGPx concentration is associated with the 
severity of periodontal disease [8]. Similar to the previous study, Patel et al. [41] 
determined an increase of the eGPx concentrations in GCF and serum progressively 
from health to gingivitis and periodontitis groups and a decrease of these levels 
after nonsurgical periodontal therapy. Thus, the authors declared that the increase 
in GCF and serum eGPx can be considered as a marker of oxidative stress caused 
by periodontal infection [41]. Moreover, they noted that the significant increase 
in serum eGPx concentration in the periodontal disease can be possibly because 
of the overflow from the diseased periodontal tissues or increased production of 
eGPx by kidney proximal tubules in response to systemic oxidative stress caused by 
periodontal disease [41].
2.2 Glutathione peroxidase and periodontal wound healing
Sakallıoğlu et al. [25] investigated GSH-Px profiles in the 30-day recovery period 
(at days 3, 12, 21, and 30) in an acute incisional wound model created with muco-
periosteal periodontal flaps in dogs. They determined that GSH-Px levels increased 
significantly on the 3rd day of recovery period and then decreased insignificantly 
on the 12th day and increased insignificantly on the 21st day [25]. Later, GSH-Px 
levels decreased significantly on the 30th day compared to the 21st day of the 
recovery period, and these levels are lower than the baseline [25]. It is suggested 
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that GSH-Px plays a significant role in the eradication of ROS in the recovery period 
of periodontal repair [25]. Moreover they argued that GSH-Px can neutralize to the 
noxious effects of OH in a normal periodontal mucoperiosteal or gingival wound 
healing [25].
2.3 Glutathione peroxidase, smoking, and periodontal disease
The etiology of periodontal disease is multifactorial, and periodontal patho-
genesis processes are replaced by environmental and acquired risk factors such 
as smoking [42]. Tobacco smoking is one of the principal modifiable risk factor 
associated with chronic destructive periodontal disease [36]. It has been reported 
that the prevalence of periodontitis was three to six times higher in smokers than 
nonsmokers [16]. Possible negative effects of smoking on periodontal tissues may 
include altered neutrophil function, decreased IgG production, vascular alterations, 
increased prevalence of perio-pathogens, altered fibroblast attachment and func-
tions, decreased lymphocyte proliferation, difficulty in eliminating pathogens by 
mechanical therapy, and negative local effects on cytokinesis and growth factor pro-
duction [36]. Smoking influences oxidative stress in the body by promoting oxidative 
burst in neutrophils and causes an imbalance between antioxidants and ROS [43].
Guentsch et al. [16] evaluated both GSH-Px activities in saliva and serum in 
patients with periodontitis and the effects of periodontal treatment and smoking 
on these parameters. They reported an elevated GSH-Px activity in saliva in both 
the nonsmoking and smoking periodontitis groups compared to the periodontally 
healthy control groups and that these levels, which increased in both periodontitis 
groups, decreased after treatment [16]. However, the authors did not find a signifi-
cant difference in serum GSH-Px values of both smokers and nonsmoker individu-
als with periodontitis and those who are periodontally healthy [16]. It is suggested 
that elevated GSH-Px levels in the saliva of periodontitis patients indicate to 
adversely affect antioxidant mechanisms leading to tissue damage of the continuous 
ROS production in periodontal inflammation [16]. Also, it is shown that smoking 
increased the GSH-Px levels in patients with periodontitis [16]. On the contrary, 
Aziz et al. [36] argued that smokers with CP have shown decreased GSH-Px activity 
in serum when compared to nonsmoker controls.
Hendek et al. [18] examined the effects of initial periodontal therapy on GSH-Px 
levels in serum, saliva, and GCF samples in smokers and nonsmokers with CP. They 
found that there was no significant difference among all groups for GSH-Px enzyme 
activity in serum, while GSH-Px enzyme activity in saliva and GCF was higher 
in smokers and nonsmokers with CP than periodontally healthy nonsmokers but 
statistically insignificant in GCF [18]. In addition, authors declared that there was 
no significant difference in the GSH-Px enzyme activity in GCF, serum, and saliva 
after periodontal therapy in both periodontitis groups [18]. Their data speculated 
that elevated GSH-Px activity in periodontitis patients may be a result of tissue 
repair and adaptive mechanisms against inflamed periodontal tissues in response to 
oxidative stress [18]. Conversely, Naresh et al. [43] found that the levels of GSH-Px 
in the saliva of smokers and nonsmokers with CP were decreased when compared 
with the healthy group and mean GSH-Px levels were lowest in smokers with 
CP. They stated that exposure to smoking may reduce salivary GSH-Px levels [43].
Toguç et al. [44] investigated the impact of smoking status on the GSH-Px levels 
in the gingival tissue and blood in subjects with CP. When blood GSH-Px levels are 
evaluated, the lowest values were observed in the smoker patients with CP com-
pared to nonsmoker patients with CP and in the nonsmoker control group com-
pared to nonsmokers and former smokers with CP [44]. Besides, elevated GSH-Px 
levels in gingival tissue have been determined in the control group when compared 
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with all CP groups [44]. When gingival tissue GSH-Px levels are evaluated among 
all CP groups, the lowest values were found surprisingly in nonsmokers [44]. 
Moreover, they found that there were strong negative correlations between gingival 
tissue GSH-Px levels and smoking duration and yearly cigarette consumption [44]. 
Thus, they stated that the reduced local GSH-Px levels in the periodontitis patients 
may increase with smoking, and the reason for this increase may be the result of a 
protective and adaptive mechanism developing in the tissue [44].
2.4 Glutathione peroxidase, systemic diseases, and periodontal disease
Periodontal disease has been associated with several systemic illnesses, includ-
ing atherosclerosis, cardiovascular disease, rheumatoid arthritis, diabetes mellitus, 
adverse pregnancy outcomes, and Alzheimer’s disease [12].
2.4.1 Diabetes mellitus
Diabetes mellitus (DM) is a major risk factor for periodontal diseases, and peri-
odontitis is noted as the sixth complication of DM. It has been shown with increasing 
evidence that the prevalence, progression, and severity of periodontitis increase in 
individuals with diabetes, especially uncontrolled, compared to individuals with no 
diabetes [45, 46]. There is a bilateral relationship between periodontal disease and 
DM. Various mechanisms have been suggested to clarify this relationship includ-
ing the formation of advanced glycation end products (AGEs), changes in collagen 
metabolism and immune function, and recently an increased oxidative stress [47].
Arana et al. [48] evaluated the levels of GSH-Px in the saliva of patients with 
diabetes mellitus type 2 (DM2) and healthy nondiabetic patients in the presence of 
periodontal disease. They determined that the salivary GSH-Px levels in the dia-
betic group with good metabolic control was significantly higher than the control 
group and the diabetic group with poor metabolic control, and also patients with 
poor metabolic control in comparison with the control group and well-controlled 
diabetic groups have worst periodontal health and lowest saliva GPx levels [48]. 
Authors suggested that poor metabolic control in DM2 patients is associated with 
lower levels of salivary GSH-Px and worse periodontal health [48]. On the other 
hand, Duarte et al. [47] evaluated the gene expression of GSH-Px1 in the gingival 
tissue of poorly and well-controlled type 2 diabetic subjects with CP. They found 
that the periodontitis groups presented higher expression of GSH-Px1 than the 
periodontally healthy control [47]. It is advocated that GSH-Px1 was enhanced by 
periodontitis, independently of the diabetic status of the patients [47].
2.4.2 Cardiovascular disease
A recent review has shown a positive relationship between periodontitis and car-
diovascular diseases [49]. It is determined that periodontal inflammation increases 
the development and progression of atheroma plaques via systemic bacteremia and 
lesion from the interaction of the intima with perio-pathogens entering the circula-
tion [49]. Therefore, it is noted that the presence of periodontitis may be a risk 
factor for cardiovascular diseases [50]. Moreover, oxidative stress plays an important 
role in the pathogenesis of both periodontal disease and cardiovascular diseases [51].
Punj et al. [1] investigated the levels of glutathione peroxidase in serum and 
saliva of CP patients with and without ischemic heart disease (IHD). They stated 
that salivary GSH-Px levels were increased in the IHD + CP, IHD + H, and CP 
groups when compared with the healthy controls, whereas the serum GSH-Px levels 
were increased in the healthy group when compared with IHD + CP, IHD + H, 
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and CP groups [1]. Authors indicated that this situation could probably be a result 
of a curative increase of GSH-Px to the oxidant stress in diseased states [1]. They 
emphasized that increased oxidative stress in the presence of chronic periodontitis 
may cause endothelial dysfunction of the blood vasculature, predisposing to athero-
sclerotic plaque formation and increasing predisposition to ischemic heart disease 
[1]. Köse et al. [52] examined the influences of periodontitis on levels of cardiac 
oxidative stress. Authors found that GSH-Px levels in the heart ventricular tissue of 
the rats with experimental periodontitis were higher than that of control group but 
statistically insignificant [52]. They argued that this increase could be associated 
with adaptive response [52]. Moreover, they speculated that oxidative stress in the 
cardiac tissue may be the result of an increase in the amount of ROS rather than a 
decrease in antioxidant levels [52].
2.4.3 Pregnancy
Various studies have proven a possible bidirectional association with periodontal 
disease and pregnancy [53]. It is supported that periodontal diseases are related 
with adverse pregnancy effects [54]. One of the possible mechanisms underlying 
this interaction stated that there may be oxidative stress-related inflammation 
pathways in case of pregnancy and periodontal disease [5, 27]. Oxidative stress is 
a principal supporting factor in the pathogenesis of preeclampsia and periodontal 
disease [27]. Çanakçı et al. [40] evaluated the GSH-Px levels in serum, saliva, 
and GCF in preeclamptic and normotensive pregnant women with and without 
periodontal disease. They determined that the GSH-Px activities in the serum and 
GCF of the periodontally healthy normotensive women were higher than that of 
preeclamptic and normotensive women with periodontal disease and periodontally 
healthy preeclamptic women [40]. There was no significant differences in saliva 
GSH-Px activities among all groups [40]. They declared that systemic and local 
GSH-Px activities reduced with the effect of periodontal disease in addition to the 
impact of preeclampsia [40]. Similarly Shetty et al. [27] observed that the GSH-Px 
activity in serum and saliva elevated in normotensive pregnant women with healthy 
periodontium when compared with preeclampsia pregnant women with and 
without periodontitis, and also preeclamptic women with periodontitis group have 
the lowest values but statistically nonsignificant. They indicated that periodontal 
diseases which cause a reduction in antioxidant levels could be a likelihood risk 
factor for severity, progression, and even initiation of preeclampsia [27].
Gümüş et al. [5] examined the salivary GSH-Px levels of the pregnant and 
postpartum women and their link with clinical parameters of periodontal inflam-
mation and disease severity. They assigned that the GSH-Px levels were increased in 
the postpartum group when compared with pregnant and nonpregnant groups and 
in the nonpregnant group when compared with pregnant group [5]. Furthermore, 
they found that salivary GSH-Px levels were positively correlated with PD and BOP 
and total bacterial numbers in the postpartum group and with PD, CAL, BOP, or 
PI in the nonpregnant women group [5]. Conversely authors did not find associa-
tion between GPx levels and periodontal disease status in pregnant women [5]. It is 
determined that salivary GSH-Px levels, which were at low levels during pregnancy, 
increased in the postpartum [5]. They speculated that this may be due to a healing 
mechanism against the exposure of tissues to excessive ROS during pregnancy [5].
2.5 Glutathione peroxidase, medication, and periodontal disease
Drug-induced gingival enlargement is previously reported as side effect of 
immunosuppressive agents such as cyclosporine A (CsA) and tacrolimus, calcium 
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channel blockers such as amlodipine and nifedipine, and anticonvulsant drugs such 
as phenytoin [55]. It has been stated that overgrowth develops due to the increase in 
collagen accumulation and decrease in collagenase enzyme activity after drug use 
[55]. Gingival and periodontal inflammation may increase, as excessive gingival 
enlargement will complicate oral hygiene practices [55]. Sobeniec et al. [56] evalu-
ated the GSH-Px activity in serum and saliva in patients with periodontal disease 
treated due to epilepsy. They determined that serum and saliva GSH-Px activities 
decreased in these patients with excessive gingival enlargement when compared 
with the control group [56]. On the other hand, Sardarian et al. [26], an in vitro 
study, determined that the low concentration of CsA (0.1 mg/mL) had no effect on 
GSH-Px activity in the oral epithelium while the activity was significantly increased 
at higher concentrations (1 mg/mL). They argued that GSH-Px activity increased to 
eliminate increased ROS in the oral epithelium after treatment with CsA [26].
In an experimental study, rats were infected with multibacterial inoculum 
containing PG, TD, and TF, as an oral lavage every other week for 12 weeks [12]. 
Afterward, daily subcutaneous injections of enoxacin, bis-enoxacin, alendronate, 
or doxycycline were administered for 6 weeks after 6 weeks of multibacterial infec-
tion in rats [12]. Subsequently, they evaluated the levels of GSH-Px in the serum of 
the infected, treated, and sham-infected rats [12]. Consequently, it is determined 
that serum levels of GSH-Px increased in rats infected with periodontal bacteria 
when compared with sham-infected rats and reduced in treated rats compared 
to infected and untreated rats [12]. Authors stated that elevated GSH-Px activity 
protects the periodontal tissues averse to oxidative stress [12].
Host modulatory therapy (HMT) is a treatment method that aims to decrease 
tissue destruction and stabilize the periodontium by arranging the components of 
the host response [57]. HMTs may be categorized as anti-inflammatory drugs, bone-
stimulating agents (bisphosphonates), and anti-proteinase agents, such as low-dose 
doxycycline (LDD) [58]. Caffeic acid phenethyl ester (CAPE) has antioxidant, 
antitumoral, anti-inflammatory, and immunomodulatory properties and inhibits 
ROS production during inflammatory processes [59]. Recently, it has been reported 
that CAPE can modulate the host response [60]. Yiğit et al. [19] evaluated the effects 
of LDD and CAPE on alveolar bone level and the plasma levels of GSH-Px activity 
in an experimental periodontitis rat model. They determined that GSH-Px levels in 
plasma increased in the CAPE + periodontitis group, but decreased in the periodon-
titis and periodontitis + LDD groups when compared to control group [19]. The 
authors stated that CAPE significantly increased GSH-Px levels and CAPE may have 
more antioxidant properties than LDD in periodontal inflammation [19].
A previous study showed the creation of fast reepithelization on the human 
gingival wounds of the topical application of 1% taurine (2-amino ethane sulfonic 
acid) [61]. Sree and Sethupathy [62] investigated the effect of taurine as an anti-
oxidant in the management of patients with the chronic periodontitis. For this 
purpose, they evaluated GSH-Px levels in the plasma and gingival tissue before and 
after administration of taurine [62]. They reported that decreased GSH-Px levels 
in plasma and gingival tissue were determined after taurine administration [62]. It 
is suggested that taurine enhanced the antioxidant status of chronic periodontitis 
patients by affecting GSH-Px antioxidant levels [62].
While melatonin has a direct neutralizing effect against ROS, it has an indirect 
effect by increasing the effectiveness of GSH-Px [63]. Özdem et al. [64] investigated 
the GSH-Px levels in the heart tissues after melatonin application after induction 
of experimental periodontitis in the rats. They found that the GSH-Px levels in 
heart tissue were higher in the periodontitis + melatonin group compared to peri-
odontitis + saline solution group and in the healthy + melatonin group compared to 
healthy + saline solution group, while there were no significant differences between 
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healthy + saline solution and periodontitis + saline solution groups [64]. In line with 
these results, the authors claimed that application of melatonin caused an increase in 
GSH-Px levels in the heart tissue either due to its antioxidant properties or by increas-
ing the synthesis of antioxidant enzymes [64]. Furthermore, Kırzıoğlu et al. [24] 
examined the effects of systemically administered rosuvastatin, which decreases the 
levels of ROS and increases antioxidant activity, on GSH-Px levels in the serum of the 
rats with experimental periodontitis. They reported there were no significant differ-
ences in the levels of GSH-Px among control, healthy + rosuvastatin, periodontitis, 
and periodontitis + rosuvastatin groups [24].
3. Conclusions
There is a growing evidence for the role of ROS in the pathogenesis of periodon-
tal diseases. The short half-life of ROS limits its measurability in biological fluids in 
the periodontal disease. Therefore, it is stated that it is more reliable to measure the 
products of ROS-induced tissue damage and levels of antioxidants in the periodon-
tal disease. One of the most frequently detected enzymatic antioxidants in peri-
odontal disease is GSH-Px. Previous studies found that GSH-Px levels in different 
biological fluids increased, decreased, or are unchanged in individuals with peri-
odontal disease compared to control groups. The reason for this contradiction might 
be linked to the difference in the analyses applied between studies and the presence 
of various dynamic processes in progression of periodontal disease. Nevertheless, 
the common result in the studies stated that GSH-Px protects periodontal tissues 
against oxidative stress and plays an important role in the progression of periodon-
tal disease. Thus, it was emphasized that GSH-Px can be a reliable biomarker in 
biological fluids to evaluate periodontal status and results of periodontal treatment. 
However, further studies in long term using large population are needed in order 
to better understand how GSH-Px contributes to the development of periodontal 
diseases using knockout and knockdown techniques.
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